en
Scientific article
English

Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects

Published inEuropean journal of clinical investigation, vol. 36 Suppl 3, p. 25-31
Publication date2006
Abstract

Bosentan is an effective first-line therapy in New York Heart Association (NYHA) III patients with idiopathic pulmonary arterial hypertension (PAH). Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD).

Keywords
  • Adolescent
  • Adult
  • Antihypertensive Agents/administration & dosage
  • Child
  • Drug Therapy, Combination
  • Exercise Test/methods
  • Female
  • Heart Defects, Congenital/complications/physiopathology
  • Humans
  • Hypertension, Pulmonary/complications/drug therapy/physiopathology
  • Male
  • Middle Aged
  • Prostaglandins, Synthetic/therapeutic use
  • Pulmonary Circulation/drug effects
  • Retrospective Studies
  • Sulfonamides/administration & dosage
  • Treatment Outcome
  • Vascular Resistance/drug effects
  • Walking/physiology
Citation (ISO format)
SITBON, O et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. In: European journal of clinical investigation, 2006, vol. 36 Suppl 3, p. 25–31. doi: 10.1111/j.1365-2362.2006.01685.x
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0014-2972
430views
0downloads

Technical informations

Creation02/03/2015 2:19:00 PM
First validation02/03/2015 2:19:00 PM
Update time03/14/2023 10:52:02 PM
Status update03/14/2023 10:52:02 PM
Last indexation01/16/2024 4:51:22 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack